-
Forex Expo Dubai to Take Place as Scheduled on 22–23 September 2026
-
Ethiopia boosts drone production to fight rebels
-
Russia pounds Kyiv, ending three-day halt for US talks
-
Yemen rebels hit Saudi Arabia with wave of strikes, wounding 73
-
Flights resume gradually in Indonesia after volcanic eruption
-
Nepalis mark a year since deadly protests that toppled government
-
French AI firm Mistral valued at 21 bn euros after latest funding
-
Rubio launches Latin America tour to cement US influence
-
Sweden heads to the polls in close election race
-
France tries 14 over deadliest Channel migrant crossing disaster
-
Australia's Big Bash T20 teams face sale to private investors
-
Australia threatens hefty fines if big tech fails 'duty of care'
-
Russia resumes strikes on Kyiv after three-day halt
-
Zverev romps into quarter-finals as Darderi downed
-
Canada's counter-tariffs take effect on various US goods
-
Kauai on tornado watch as Hurricane Lowell nears Hawaiian islands
-
China's trade booms as focus turns to expected Trump-Xi summit
-
Pakistan roll the dice in search of consolation win over England
-
Is Champions League three-peat really possible for PSG?
-
Yen extends gains as traders eye rate hike, tech rallies again
-
Russia pummels Kyiv after three-day halt
-
'The ber months': Christmas arrives early in the Philippines
-
Mongolians wait hours for fuel as reliance on Russia bites
-
N. Korea calls Russia bridge a sign of tighter ties
-
Blockx first Belgian man to reach US Open quarter-finals
-
US sanctions threaten to crush Iranian students' dreams
-
Praying for rain as fires, haze plague Indonesian Borneo
-
Former champ Gauff holds off Jovic to reach US Open quarter-finals
-
Rybakina tops Osaka, sets US Open quarter-final clash with Zheng
-
Equitech-Bio Expands Reagent Portfolio with New IgG Offering and Publication-Backed Product Validation from Bioz
-
Apex Expands Trinity Zone with Step-out Hole Returning 197.5 m Interval of 2.12% REO at the Rift Rare Earth Project in SE Nebraska
-
Battery X Metals to Appoint Accomplished Technology and Consumer Brands Executive Nicholas Reichenbach to Board of Directors
-
BioNxt Advances Sublingual Everolimus ODF for Organ Transplant Rejection with Initiation of Large-Animal Pharmacokinetic Study
-
Guardian Metal Resources PLC Announces Admission to FTSE AIM 50 Index
-
Genflow Biosciences PLC Announces Primary Endpoint in SLAB Clinical Trial Met
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - September 08
-
Gaming Realms PLC Announces Interim Results
-
Osaka seeks answers to nagging achilles injury after US Open exit
-
Panama Canal considering more cuts in transits due to El Nino
-
Flight data recorders recovered from Amazon cargo plane crash
-
Maresca agrees with Haaland that players started season jaded
-
Super Bowl rematch kicks off NFL season as league expands global reach
-
Hurricane warning issued for westernmost Hawaiian islands
-
Alcaraz faces Shelton in blockbuster US Open quarter-final
-
UK PM denounces 'politics of poison' after anti-migrant protests
-
Trump threatens sales in US of Canadian aircraft maker Bombardier
-
Comeback queen Zheng strikes again for US Open quarter-final berth
-
Eiffel Tower closed in row over women removed for Hindu group
-
Third absence for injured Hadjar as Lawson fills in again in Spain
-
Willemse replaces Kolbe for Springboks' All Blacks series decider
US Supreme Court skeptical of restrictions on abortion pill
The US Supreme Court appeared poised on Tuesday to reject restrictions imposed by a lower court on an abortion pill widely used in the United States to terminate pregnancies.
Dozens of demonstrators gathered outside as the nation's highest court heard its first significant abortion case since the justices overturned the constitutional right to the procedure nearly two years ago.
A majority on the conservative-dominated court appeared skeptical during 90 minutes of oral arguments about the legal standing of the anti-abortion groups and doctors who brought the case against the abortion pill mifepristone.
The abortion opponents are seeking to restrict access to mifepristone, claiming it is unsafe and anti-abortion doctors are being forced to violate their conscience by intervening on patients who suffer complications from using the abortion pill.
"These are life-threatening situations in which the choice for a doctor is either to scrub out and try to find someone else, or to treat the woman who's hemorrhaging," said Erin Hawley, a senior counsel at Alliance Defending Freedom representing the anti-abortion groups.
Solicitor General Elizabeth Prelogar, representing the administration of President Joe Biden, countered that such a scenario was "remote" and abortion opponents are unable to "identify a specific doctor who faces imminent harm."
"They have said that they fear that there might be some emergency room doctor somewhere, someday, who might be presented with some woman who is suffering an incredibly rare complication, and that the doctor might have to provide treatment," Prelogar said.
A conservative US District Court judge in Texas, an appointee of Republican presidential candidate Donald Trump, issued a ruling last year that would have banned mifepristone, which was approved by the Food and Drug Administration (FDA) in 2000.
An appeals court overturned the outright ban because the statute of limitations on challenging the FDA's approval had expired but imposed restrictions on access to the drug.
The conservative appeals court reduced the period during which mifepristone can be used from 10 weeks of pregnancy to seven weeks, blocked it from being delivered by mail and required the pill to be prescribed and administered by a doctor.
- 'FDA's gold standard review' -
Justice Ketanji Brown Jackson, a liberal, said she was worried that there is a "significant mismatch in this case between the claimed injury and the remedy that's being sought."
"What (the anti-abortion doctors) are asking for here is that in order to prevent them from possibly ever having to do these kinds of procedures everyone else should be prevented from getting access to this medication," Jackson said.
Justice Neil Gorsuch, a conservative, expressed similar concerns.
"This case seems like a prime example of turning what could be a small lawsuit into a nationwide legislative assembly on an FDA rule or any other federal government action," Gorsuch said.
Jessica Ellsworth, a lawyer for Danco Laboratories, the mifepristone manufacturer, said she had "significant concerns" about courts replacing the scientific judgment of experts and the "FDA's gold standard review process."
Only two justices -- conservatives Clarence Thomas and Samuel Alito -- appeared sympathetic to the anti-abortion groups which brought the suit against the FDA's approval of mifepristone.
"You think the FDA is infallible?" Alito asked Ellsworth at one point.
Medication abortion accounted for 63 percent of the abortions in the country last year, up from 53 percent in 2020, according to the Guttmacher Institute.
Some 20 states have banned or restricted abortion since the Supreme Court in June 2022 overturned the landmark Roe v. Wade ruling that enshrined the constitutional right to abortion for half a century.
Polls repeatedly show a clear majority of Americans support continued access to safe abortion, even as conservative groups push to limit the procedure or ban it outright.
The Supreme Court is expected to issue a decision in the abortion pill case by the end of June -- four months before the presidential election in which abortion is almost certain to be a major topic.
H.Thompson--AT